tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Ultragenyx Pharmaceutical’s Setrusumab: A Promising Buy with Potential for Significant Fracture Reduction in Osteogenesis Imperfecta
PremiumRatingsUltragenyx Pharmaceutical’s Setrusumab: A Promising Buy with Potential for Significant Fracture Reduction in Osteogenesis Imperfecta
18d ago
Ultragenyx price target lowered to $128 from $136 at Canaccord
Premium
The Fly
Ultragenyx price target lowered to $128 from $136 at Canaccord
21d ago
Ultragenyx Pharmaceutical’s Promising Growth and Financial Outlook: Analyst Recommends Buy
Premium
Ratings
Ultragenyx Pharmaceutical’s Promising Growth and Financial Outlook: Analyst Recommends Buy
22d ago
Ultragenyx backs FY25 revenue view $640M-$670M, consensus $649.53M
PremiumThe FlyUltragenyx backs FY25 revenue view $640M-$670M, consensus $649.53M
23d ago
Ultragenyx Pharmaceutical’s Promising Outlook: Buy Rating Affirmed Amidst Aspire Study Progress
Premium
Ratings
Ultragenyx Pharmaceutical’s Promising Outlook: Buy Rating Affirmed Amidst Aspire Study Progress
25d ago
RARE Earnings this Week: How Will it Perform?
Premium
Pre-Earnings
RARE Earnings this Week: How Will it Perform?
26d ago
Ultragenyx Pharmaceutical: Buy Rating Affirmed Amid Manageable FDA Setbacks and Promising Clinical Data
PremiumRatingsUltragenyx Pharmaceutical: Buy Rating Affirmed Amid Manageable FDA Setbacks and Promising Clinical Data
2M ago
Ultragenyx participates in a conference call with JPMorgan
Premium
The Fly
Ultragenyx participates in a conference call with JPMorgan
2M ago
Ultragenyx price target lowered to $79 from $80 at BofA
Premium
The Fly
Ultragenyx price target lowered to $79 from $80 at BofA
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100